Immunomodulatory News and Research

RSS

New cannabis-based drug shows promise for pancreatic cancer

Cancer of the pancreas is a particularly deadly cancer, claiming over 90% of its victims within 5 years from diagnosis. It resists most standard therapies, including surgery, chemotherapy, radiation therapy, immunotherapy and targeted therapy, and metastasizes early, often before being diagnosed. A cure is possible only with very localized tumors.

22 Aug 2019

Study finds new way to help cancer doctors predict blood clots in patients with multiple myeloma

New research from the Hutchinson Institute for Cancer Outcomes Research- which is based at Fred Hutchinson Cancer Research Center- along with the University of Washington and the Seattle Cancer Care Alliance, identifies a simple way to help cancer doctors caring for patients with multiple myeloma to predict blood clots in order to take preventive action.

19 Jul 2019

$FDA grants accelerated approval to new treatment for refractory multiple myeloma$

FDA grants accelerated approval to new treatment for refractory multiple myeloma

Today, the U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

3 Jul 2019

Endogenous retrovirus type W found to be a major contributor to nerve damage in MS

Early disease stages of MS are primarily characterized by immune cell infiltration of the CNS. This causes inflammation that damages the so-called myelin sheaths.

28 Jun 2019

Complement system shown to remove dead cells in retinitis pigmentosa, contradicting previous research

Researchers have found that the complement system seems to protect against retinal degeneration in retinitis pigmentosa.

18 Jun 2019

UAB researchers awarded $2.3 million grant to study macrophage circadian rhythms in heart failure

Researchers at the University of Alabama at Birmingham have been awarded a four-year, $2.3 million grant from the National Heart, Lung and Blood Institute to study macrophage circadian rhythms in heart failure.

13 Jun 2019

Research reveals immunomodulatory role of ent-kaurane diterpenoids toward NK cells

As early responders in the surveillance of malignant cells, natural killer cells play a significant role in the control of transformed cells at the tumor initiation stage through direct cytolysis. For this reason, NK cell-based immunotherapy is a potential therapeutic strategy for tumor sufferers.

31 May 2019

Angiotensin receptor blockers could improve response to cancer immunotherapy

A research team led by investigators at Massachusetts General Hospital and the Massachusetts Institute of Technology has found that combining a specialized version of an antihypertension drug with immune checkpoint blockers could increase the effectiveness of cancer immunotherapies.

30 Apr 2019

DNA rearrangement may predict poor outcomes in multiple myeloma

A certain type of DNA marker predicts poor outcomes in multiple myeloma, researchers at Winship Cancer Institute, Emory University have found.

24 Apr 2019

Study reveals immune evasion strategy developed by cytomegaloviruses

Owl monkey cytomegalovirus produces a decoy molecule A43 to evade detection and destruction by immune cells in their hosts, according to a study published April 4 in the open-access journal PLOS Pathogens by Ana Angulo of the University of Barcelona, and colleagues.

8 Apr 2019

Nanovaccine boosts immunity in mice with gut microbiome-mediated metabolic syndrome

A new class of biomaterial developed by Cornell researchers for an infectious disease nanovaccine effectively boosted immunity in mice with metabolic disorders linked to gut bacteria - a population that shows resistance to traditional flu and polio vaccines.

29 Mar 2019

Research reveals how metabolites can be used to inhibit epigenetic mechanisms and treat MS

Understanding and mitigating the role of epigenetics (environmental influences that trigger changes in gene expression) in disease development is a major goal of researchers.

28 Feb 2019

Quanterix extends oncology footprint with accelerated launch of next gen SP-X platform and CorPlex validated 10-Plex

Quanterix announce launch of its Simoa SP-X Imaging and Detection System, 10-Plex Simoa CorPlex Cytokine Panel, and broad menu of additional multiplex panels.

From Quanterix 10 Jan 2019

Potential combination therapy against rare disease of the bone marrow could improve treatment

Myelofibrosis is a severe and very rare hematological disease for which treatment has only been partially effective to date. Its low incidence rate is one of the reasons why effective therapies are still lacking.

19 Dec 2018

GW researchers review studies on treatments for prurigo nodularis

Prurigo nodularis is a disabling chronic skin condition characterized by severely itchy, crusty, firm papules and nodules that often occur on the arms and legs, but can appear diffusely on the body. The pathogenesis of prurigo nodularis is poorly understood, as this condition has been associated with a broad array of primary skin and underlying medical diseases affecting the liver, kidneys, and blood.

13 Dec 2018

New ointment for treating brown recluse spider bites is tested on humans

The bite from a brown recluse spider (Loxosceles) can cause skin necrosis, renal failure, and even death. A new ointment is being tested in Brazil, however. Its effects have already been proven in tests conducted in cell cultures and animal models.

29 Nov 2018

Research shows link between immune responses and environmental exposures early in life

The prevalence of allergic diseases has increased significantly over the last decades, creating substantial financial and societal burdens. Due to this, researchers are trying to discover new approaches to the prevention and treatment of these diseases.

22 Nov 2018

Researchers develop novel mouse model to study immunomodulatory therapies

Because mice do not respond to immunomodulatory drugs, preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice.

19 Nov 2018

Alivio Therapeutics receives DoD grant to advance development of new therapy for IC/BPS

Alivio Therapeutics, an affiliate of PureTech Health plc developing therapies to treat inflammatory disorders through targeted disease immunomodulation, today announced a $3.3 million U.S. Department of Defense Technology/Therapeutic Development Award to advance Alivio's product candidate, ALV-107, for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.

12 Sep 2018

Mouse study suggests new therapeutic approach to treat heart failure

A heart attack triggers an acute inflammatory response, followed by resolution of inflammation and wound healing. A severe heart attack, however, can cause chronic and sustained inflammation that leads to heart failure and death.

10 Sep 2018